what are the risks of glp 1 GLP-1: Diabetes Drug Changing How We Think About Weight Loss Your guide to GLP-1 side

Home Wirkstoffgruppen Glucagon-like peptide 1 (GLP-1-)Rezeptoragonisten (Inkretinmimetika) werden zur Behandlung von Diabetes mellitus Typ 2 in Kombination mit anderen Antidiabetika oder als Monotherapie, wenn Metformin nicht indiziert ist, eingesetzt

Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus

248,249 It is involved in various chronic diseases

And the studies are obviously very positive for results as long as you maintain the medication for a lifetime, which is required to sustain just like the other health improvements

And in 2025, Wegovy also received FDA accelerated approval for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, underscoring that these medications can impact disease processes well beyond body weight alone